ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
AstraZeneca and Daiichi Sankyo’s ENHERTU additionally improved median general survival by greater than 6 months vs. chemotherapy in all sufferers evaluated in DESTINY-Breast04 ENHERTU met the first endpoint of progression-free ...